ライフサイエンスコーパス: type I procollagen

1 at least one ligand in extracellular matrix (type I procollagen).

2 omplex involved in prolyl 3-hydroxylation in type I procollagen.

3 RNA, but markedly increased the half-life of type I procollagen.

4 nd showed a 3-fold increase in intracellular type I procollagen.

5 RNA expression, secretion, or processing of type I procollagen.

6 by TGF-beta, thereby reducing expression of type I procollagen.

7 both propeptide chains that constitute human type I procollagen.

8 ne the association profile between Hsp47 and type I procollagen.

9 lagenase, respectively) and synthesized less type I procollagen (36 and 88% reduction, respectively,

10 Type I procollagen accumulates in the Golgi of fibroblas

11 revealed less fibrosis and less staining for type I procollagen after imatinib mesylate treatment, bu

12 for the prominence of a homotrimeric form of type I procollagen (alpha1 trimer) during vertebrate dev

13 gen telopeptide, aminoterminal propeptide of type I procollagen, aminoterminal propeptide of type III

14 ls was further examined by colocalization of type I procollagen and bromodeoxyuridine labeling to act

15 y reduced telopeptide lysyl hydroxylation of type I procollagen and collagen cross-linking in tendons

16 vated CYR61 expression substantially reduces type I procollagen and concurrently increases matrix met

17 These cells synthesize type I procollagen and degrade it intracellularly; howev

18 hetic activity manifested by the presence of type I procollagen and elastin at 3 months after injury.

19 ecules such as lysyl oxidase family members, type I procollagen and fibronectin in response to transf

20 n that binds the COOH-terminal propeptide of type I procollagen and potentiates its cleavage by proco

21 ng growth factor-beta pathway, which reduced type I procollagen and raised MMP-1 expression.

22 Tropoelastin, type I procollagen and TGF-beta gene expression, and ang

23 ively during posttranslational maturation of type I procollagen and that FKBP65 and HSP47 but fail to

24 enuates UV irradiation-induced inhibition of type-I procollagen and upregulation of MMP-1.

25 pplement to obtain high expression levels of type I procollagen as heat-stable heterotrimers in Sacch

26 rmal extracellular matrix because it cleaves type I procollagen, as well as other precursor proteins.

27 onitors the integrity of the triple helix of type I procollagen at the ER/cis-Golgi boundary and, whe

28 is study, we first searched for mutations in type I procollagen by analyses of protein and mRNA in fi

29 monstrated by a lower in vitro production of type I procollagen by dermal fibroblasts isolated from s

30 n that potentiates enzymatic cleavage of the type I procollagen C-propeptide by bone morphogenetic pr

31 nces the enzymatic activity that cleaves the type I procollagen C-propeptide, was previously mapped t

32 rphogenetic protein-1 (BMP-1), also known as type I procollagen C-proteinase ().

33 no-acid protein that has 43% identity to the Type I procollagen C-proteinase enhancer protein (PCOLCE

34 cleotide sequences homologous to that of the type I procollagen C-proteinase enhancer protein (PCPE)

35 A novel human Type I procollagen C-proteinase enhancer protein-like ge

36 but rather in the most C-terminal domains of type I procollagen chains.

37 genes SERPINH1 and FKBP10, which encode the type I procollagen chaperones HSP47 and FKBP65, respecti

38 lants of MSFs from transgenic mice harboring type I procollagen-chloramphenicol acetyltransferase con

39 of BMP1 deficiency upon C-term propeptide of type I procollagen (CICP) production in the fibrotic mou

40 radiation from the sun reduces production of type I procollagen (COLI), the major structural protein

41 lse-chase experiments, the newly synthesized type I procollagen, composed of pro alpha 1(I) and pro a

42 The carboxyl-terminal propeptide of type I procollagen (CPP-I) plays a key role in regulatio

43 NA is shown to differ from that of BMP-1 and type I procollagen during mouse development, consistent

44 layer; medium fractions showed no detectable type I procollagen during the entire 120-minute chase.

45 a coordinate decrease in CTGF, TGF-beta, and type I procollagen expression and content.

46 -beta/Smad/CTGF axis likely mediates reduced type I procollagen expression in aged human skin in vivo

47 irradiation and precedes down-regulation of type I procollagen expression in human skin in vivo.

48 ata indicate that in human skin fibroblasts, type I procollagen expression is dependent on endogenous

49 contrast, overexpression of CTGF stimulated type I procollagen expression, and increased promoter ac

50 coincident temporal and spatial overlap with type I procollagen expression, implicating this cytokine

51 Repeated UV-A1 exposures did not suppress type I procollagen expression.

52 hibitory Smad7 abolished CTGF stimulation of type I procollagen expression.

53 Regulation of type I procollagen gene (COL1A2) transcription by TGF-be

54 from the same individuals were assessed for type I procollagen gene expression by in situ hybridizat

55 We examined type I procollagen gene expression in human atherosclero

56 expression protects against UV inhibition of type I procollagen gene expression in human skin fibrobl

57 marked suppression of lung tropoelastin and type I procollagen gene expression in the presence of AC

58 did not alter matrix metalloproteinase 1 or type I procollagen gene expression.

59 cases result from dominant mutations in the type I procollagen genes, but mutations in a growing num

60 The folding mechanism of type I procollagen has been well characterized, and prot

61 tide, is essential for efficient assembly of type I procollagen heterotrimers.

62 This study shows that MAGP-2 stabilizes type I procollagen, identifying an important function of

63 cient for correct assembly and processing of type I procollagen in a eucaryotic system that does not

64 his was followed by a sustained synthesis of type I procollagen in neointima beginning at 7 days and

65 sed for 120 minutes demonstrated no trace of type I procollagen in the cell layer; medium fractions s

66 s and release both C- and N-propeptides from type I procollagen in vitro and in vivo and contribute t

67 g activity against Chordin, probiglycan, and type I procollagen in vitro.

68 lopeptide cross-links of collagen type I and type I procollagen intact N-terminal propeptide, as well

69 Type I procollagen is a heterotrimer composed of two pro

70 Reduced production of type I procollagen is a prominent feature of chronologic

71 Compared with atherosclerotic plaques, type I procollagen is increased and MMP-1 is decreased i

72 individual and a population of the secreted type I procollagen is protease sensitive.

73 howed that exogenously added Sfrp2 inhibited type I procollagen maturation in primary cardiac fibrobl

74 MAGP-2 overexpression had no effect on type I procollagen messenger RNA, but markedly increased

75 Assembly of the type I procollagen molecule begins with interactions amo

76 ral part, and near the C terminus) along the type I procollagen molecule for both A-domains.

77 erely affected infant make some overmodified type I procollagen molecules.

78 d by immunohistochemistry) and expression of type I procollagen mRNA (detected by in situ hybridizati

79 tic lesions (< 1.5 years) contained abundant type I procollagen mRNA but little immunoreactive MMP-1

80 In situ hybridization for type I procollagen mRNA displayed increased gene express

81 Type I procollagen mRNA expression was demonstrated in m

82 CTGF substantially reduced the expression of type I procollagen mRNA, protein, and promoter activity.

83 eactive MMP-1 and TIMP-1 as well as abundant type I procollagen mRNA.

84 mutations in the COL1A1 and COL1A2 genes for type I procollagen, mutations have been difficult to det

85 function of the NH(2)-terminal propeptide of type I procollagen (N-propeptide) is poorly understood.

86 let-derived growth factor A (p = 0.033), and Type I procollagen (p = 0.096) were lower; and IFN-gamma

87 collagen (CTX) and N-terminal propeptide of type I procollagen (P1NP)], and inflammation defined as

88 the bone biomarkers N-terminal propeptide of type I procollagen (P1NP, r = 0.50, p < 0.0001), C-termi

89 sslinks [CTX], and N-terminal propeptides of type I procollagen [P1NP]) markers were measured.

90 BAL), fluid we investigated the synthesis of type I procollagen (PICP) and type I/II collagen degrada

91 Levels of serum C-terminal propeptide of type I procollagen (PICP) were significantly higher in m

92 N-terminal propeptide of type I procollagen (PINP) and C-telopeptide of type I co

93 on triple helix formation, human recombinant type I procollagen, pN-collagen (procollagen without the

94 pro alpha1(III)] and the pro alpha2 chain of type I procollagen [pro alpha2(I)] as examples of procol

95 CRT(-/-) MEFs also have reduced type I procollagen processing and deposition into the ex

96 t high concentration inhibited human and rat type I procollagen processing by Bmp1 in vitro.

97 as a stable heterotrimeric helix similar to type I procollagen produced in tissue culture.

98 cAMP also increased type I procollagen production and gene expression of mat

99 of human dermal fibroblasts and no effect on type I procollagen production by these cells.

100 pathway and the impact of this impairment on type I procollagen production in human skin fibroblasts,

101 In the present study, we investigated type I procollagen production in photodamaged and sun-pr

102 We next investigated whether reduced type I procollagen production was because of inherently

103 ; interstitial collagenase) were reduced and type I procollagen production was increased.

104 ion of TbetaRII, with attendant reduction of type I procollagen production, is a critical molecular m

105 e similar in their capacities for growth and type I procollagen production; and 2) the accumulation o

106 nhibitor of metalloproteinases 2, C-terminal type I procollagen propeptide (PICP), and the immature c

107 expression by in situ hybridization and for type I procollagen protein by immunostaining.

108 gen-alpha 1(I) transcripts and intracellular type I procollagen protein increased in the adventitia w

109 and produced virtually identical amounts of type I procollagen protein.

110 OL1A1 and COL1A2, which encode the chains of type I procollagen, result in dominant forms of OI, and

111 the activity of FKBP65 has several effects: type I procollagen secretion is slightly delayed, the st

112 ants with HIV, PCOLCE (enzymatic cleavage of type I procollagen) significantly increased after pitava

113 likely reflect a diminished amount of normal type I procollagen, small populations of overmodified he

114 and is associated with a marked reduction in type I procollagen synthesis and impairment in adhesion.

115 The interaction of Hsp47 with type I procollagen synthesis in CECs was also studied.

116 -beta/Smad pathway is the major regulator of type I procollagen synthesis in human skin.

117 These findings indicate that the lack of type I procollagen synthesis in sun-damaged skin is not

118 UV inhibition of type I procollagen synthesis is mediated in part by c-Ju

119 PICP was measured by ELISA as a marker of type I procollagen synthesis.

120 ctions of transforming growth factor beta on type I procollagen synthesis.

121 ithin photodamaged skin act to down-regulate type I procollagen synthesis.

122 nhibit, by an as yet unidentified mechanism, type I procollagen synthesis.

123 he collagenous extracellular matrix regulate type I procollagen synthesis.

124 Langerin bound to type I procollagen that was immunoprecipitated from fibr

125 bules behaved like Akita, while a substrate (type I procollagen) that is degraded by the ER-phagy she

126 ntly elevated gene expression of procollagen type I, procollagen type III, and alpha-smooth muscle ac

127 th HFpEF and higher C-terminal propeptide of type I procollagen values also had higher mean pulmonary

128 lloproteinase-2 and C-terminal propeptide of type I procollagen values than hypertensive controls.

129 Immunohistochemistry indicated type I procollagen was being expressed by an alpha-smoot

130 Subcellular localization of Hsp47 and type I procollagen was determined by immunofluorescent s

131 Within the parenchyma, type I procollagen was expressed uniquely within granulo

132 Type I procollagen was found to be associated with Hsp47

133 Type I procollagen was produced as a stable heterotrimer

134 se inhibitor 1, and C-terminal propeptide of type I procollagen were determined in 28 patients with H

135 They express type I procollagen, with some of them translocating to t

136 ility and post-translational modification of type I procollagen, without which bone mass and quality